Compare · ABBV vs MLTX
ABBV vs MLTX
Side-by-side comparison of AbbVie Inc. (ABBV) and MoonLake Immunotherapeutics (MLTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and MLTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $469.68B, about 354.7x MLTX ($1.32B).
- ABBV has been more active in the news (17 items in the past 4 weeks vs 6 for MLTX).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- MoonLake Immunotherapeutics
- Price
- $265.73+0.42%
- $15.56+1.27%
- Market cap
- $469.68B
- $1.32B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2020
- News (4w)
- 17
- 6
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Latest ABBV
- AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
- EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $8,177,500 worth of shares (32,710 units at $250.00) and exercised 32,710 shares at a strike of $79.02 (SEC Form 4)
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
- AbbVie upgraded by Wolfe Research with a new price target
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
- SEC Form 424B5 filed by AbbVie Inc.
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest MLTX
- Amendment: SEC Form SCHEDULE 13G/A filed by MoonLake Immunotherapeutics
- SEC Form S-8 filed by MoonLake Immunotherapeutics
- SEC Form S-3ASR filed by MoonLake Immunotherapeutics
- SEC Form 10-Q filed by MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
- Chief Scientific Officer Reich Kristian sold $22,000 worth of Class A ordinary shares (1,100 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Reich Kristian sold $1,049,960 worth of Class A ordinary shares (52,448 units at $20.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Reich Kristian sold $877,933 worth of Class A ordinary shares (43,700 units at $20.09) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Reich Kristian sold $322,261 worth of Class A ordinary shares (16,105 units at $20.01) as part of a pre-agreed trading plan (SEC Form 4)